5HT1D Receptor Antibody - #DF2706

Figure 2 5-HT mediated ferroptosis resistance is independent of canonical anti-ferroptosis pathway. A) Western blot analysis of 5-HT receptors in a panel of cancer cell lines. B) HT1080 cells expressing shRNA of 5-HT receptors were treated with RSL3 (200 nm) and 5-HT (10 µm). Cell viability was assessed 24 h thereafter using CCK8. C) Western blot analysis of arrestin β1 and arrestin β2 in 293T arrestin β1-/-, arrestin β2-/- DKO cells. D) Cell death measurement of 293T arrestin β1-/-, arrestin β2-/- DKO cells treated with RSL3 (2.5 µm) and Fer-1 (1 µm) for 8 h. E) Western blot analysis of p-mTOR and p-AMPK in a panel of cell lines upon 5-HT treatment (10 µm) for 12 h. F) RNA-seq analysis of HT1080 cells with or without 5-HT treatment (10 µm) for 12 h. G) Volcano plots showing the alteration of phospholipid components in HT1080 cells treated with 5-HT (10 µm) for 12 h.

Fig. 2. Effect of 5-hydroxytryptamine receptor 1D (HTR1D) knockdown in gastric cancer (GC) cells on HTR1D function in vitro and in vivo. Effect of HTR1D knockdown on (A) proliferation, (B) clonogenic ability, and (C) migration of AGS and MGC803 cells. Magnification of migration experiment was 200 × . (D) Subcutaneous tumor nodules were generated by subcutaneously injecting short hairpin NC (shNC) and shHTR1D-1 MGC803 cells into nude mice. (E) Tumor growth curves in shNC and shHTR1D-1 groups. (F) Weight of harvested subcutaneous tumors in shNC and shHTR1D-1 groups. (G) Immunohistochemical staining of HTR1D and Ki67 in subcutaneous tumors in shNC and shHTR1D-1 groups.

figs3.